Article

Daily Medication Pearl: Tolvaptan (Jynarque)

Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .

Indication: Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease. It is also used to treat hyponatremia in patients with heart failure or syndrome of inappropriate antidiuretic hormone.

Insight:

  • Dosing: May range from 15 mg to 120 mg, based on the initial titration or target dosage.
  • Dosage forms: Tablets 15 mg, 30 mg, 45 mg, 60 mg and 90 mg .
  • Adverse events: Most common observed adverse reactions with tolvaptan (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria, and polydipsia.
  • Mechanism of action: Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native arginine vasopressin.

Source: JYNARQUE-PI (otsuka-us.com)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com